Finally, we investigated whether NIK could be a potential therapeutic target to mitigate 3T40/IL‐4‐mediated resistance to venetoclax by treating 3T40/IL‐4‐stimulated CLL cells with the NIK‐inhibiting compound CW15337. The gene discussed is IL4; the disease is B-cell chronic lymphocytic leukemia.